益佰制药
(600594)
| 流通市值：27.92亿 | | | 总市值：27.92亿 |
| 流通股本：7.84亿 | | | 总股本：7.84亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 689,387,704.62 | 358,837,040.95 | 1,862,920,853.13 | 1,446,704,488.11 |
| 营业收入 | 689,387,704.62 | 358,837,040.95 | 1,862,920,853.13 | 1,446,704,488.11 |
| 二、营业总成本 | 742,482,846.67 | 374,652,779.96 | 2,001,366,895.95 | 1,507,739,253.7 |
| 营业成本 | 291,849,727.86 | 150,985,925.19 | 751,460,808.48 | 574,014,485.11 |
| 税金及附加 | 14,456,229.86 | 8,511,918.69 | 31,457,220.29 | 25,682,877.22 |
| 销售费用 | 270,860,570.2 | 137,626,547.14 | 822,931,542.08 | 621,405,641.58 |
| 管理费用 | 123,090,573.77 | 58,623,429.15 | 290,532,433.13 | 208,244,548.04 |
| 研发费用 | 31,516,868.25 | 13,469,997.18 | 84,269,082.59 | 62,424,046.36 |
| 财务费用 | 10,708,876.73 | 5,434,962.61 | 20,715,809.38 | 15,967,655.39 |
| 其中:利息费用 | 11,382,355.03 | 5,691,450.14 | 23,374,518.45 | 17,414,473.41 |
| 其中:利息收入 | 1,068,361.22 | 485,260.48 | 3,767,249.28 | 2,788,148.66 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -80,051.75 | -5,196.72 | -214,599.61 | -360,755.35 |
| 资产处置收益 | 1,827,269.37 | 1,836,628.72 | -27,210,380.43 | -19,356,618.36 |
| 资产减值损失(新) | -30,578,373.02 | -12,212,528.62 | -159,485,265.14 | -23,878,141.91 |
| 信用减值损失(新) | 288,333.69 | 47,826.78 | -2,794,771.52 | -2,798,355.96 |
| 其他收益 | 7,451,488.12 | 4,244,601.78 | 24,168,885.77 | 17,511,400.42 |
| 四、营业利润 | -74,186,475.64 | -21,904,407.07 | -303,982,173.75 | -89,917,236.75 |
| 加:营业外收入 | 3,011,527.74 | 1,363,626.27 | 4,710,784.35 | 3,169,170.59 |
| 减:营业外支出 | 1,897,716.12 | 334,699.8 | 12,476,946.3 | 6,268,541.07 |
| 五、利润总额 | -73,072,664.02 | -20,875,480.6 | -311,748,335.7 | -93,016,607.23 |
| 减:所得税费用 | 5,387,915.87 | 8,087,807.44 | 23,593,549.41 | -2,386,803.26 |
| 六、净利润 | -78,460,579.89 | -28,963,288.04 | -335,341,885.11 | -90,629,803.97 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -78,460,579.89 | -28,963,288.04 | -335,341,885.11 | -90,629,803.97 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -80,337,813.1 | -29,524,902.89 | -329,562,325.95 | -86,562,621.79 |
| 少数股东损益 | 1,877,233.21 | 561,614.85 | -5,779,559.16 | -4,067,182.18 |
| 扣除非经常损益后的净利润 | -87,454,282.99 | -34,801,324.57 | -325,096,335.78 | -84,450,585.59 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.1 | -0.04 | -0.42 | -0.11 |
| (二)稀释每股收益 | -0.1 | -0.04 | -0.42 | -0.11 |
| 八、其他综合收益 | 7,181.75 | - | -164,440.9 | -16,696.42 |
| 归属于母公司股东的其他综合收益 | 7,181.75 | - | -164,440.9 | -16,696.42 |
| 九、综合收益总额 | -78,453,398.14 | -28,963,288.04 | -335,506,326.01 | -90,646,500.39 |
| 归属于母公司股东的综合收益总额 | -80,330,631.35 | -29,524,902.89 | -329,726,766.85 | -86,579,318.21 |
| 归属于少数股东的综合收益总额 | 1,877,233.21 | 561,614.85 | -5,779,559.16 | -4,067,182.18 |
| 公告日期 | 2026-08-21 | 2026-04-23 | 2026-04-23 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |